Bellicum Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Bellicum Pharmaceuticals has been growing earnings at an average annual rate of 44.5%, while the Biotechs industry saw earnings growing at 15.5% annually. Revenues have been declining at an average rate of 0.8% per year.

Key information

44.5%

Earnings growth rate

64.3%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	-0.8%
Return on equity	-486.1%
Net Margin	-1,484.0%
Last Earnings Update	30 Sep 2023

Recent past performance updates

Recent updates

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Aug 11

Bellicum launches $25M underwritten offering

Oct 29

Revenue & Expenses Breakdown
Beta

How Bellicum Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:BLCM Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Sep 23	2	-22	7
30 Jun 23	2	-29	7
31 Mar 23	2	-25	6
31 Dec 22	2	-25	6
30 Sep 22	2	-16	6
30 Jun 22	6	-8	6
31 Mar 22	6	-6	6
31 Dec 21	6	-10	7
30 Sep 21	6	7	9
30 Jun 21	1	4	11
31 Mar 21	1	-37	13
31 Dec 20	1	-8	16
30 Sep 20	5	-55	18
30 Jun 20	5	-87	23
31 Mar 20	7	-70	27
31 Dec 19	7	-112	30
30 Sep 19	2	-111	31
30 Jun 19	3	-102	29
31 Mar 19	1	-100	27
31 Dec 18	1	-98	25
30 Sep 18	1	-93	23
30 Jun 18	1	-92	21
31 Mar 18	0	-93	21
31 Dec 17	0	-92	21
30 Sep 17	0	-90	20
30 Jun 17	0	-84	20
31 Mar 17	0	-76	19
31 Dec 16	0	-69	17
30 Sep 16	0	-66	17
30 Jun 16	0	-62	16
31 Mar 16	0	-56	15
31 Dec 15	0	-49	13
30 Sep 15	0	-106	11
30 Jun 15	1	-97	8
31 Mar 15	1	-90	6
31 Dec 14	2	-85	4
30 Sep 14	3	-14	3
30 Jun 14	3	-12	3
31 Mar 14	2	-10	3
31 Dec 13	2	-9	2

Quality Earnings: BLCM is currently unprofitable.

Growing Profit Margin: BLCM is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BLCM is unprofitable, but has reduced losses over the past 5 years at a rate of 44.5% per year.

Accelerating Growth: Unable to compare BLCM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLCM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).

Return on Equity

High ROE: BLCM has a negative Return on Equity (-486.06%), as it is currently unprofitable.

Bellicum Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

Earnings released

Recent updates

Bellicum Pharmaceuticals Files Form 15

The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).

Nasdaq to Delist the Common Stock of Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite Index

Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)

Consensus EPS estimates fall by 39%

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers Symposium

Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

Price target decreased to US$5.00

Insufficient new directors

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$5.00

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Provides an Operational Update

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

New 90-day high: US$4.65

Price target lowered to US$4.50

Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020

Bellicum launches $25M underwritten offering

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

New 90-day low - US$6.28

Earnings released

The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM).

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta